$1.92
-0.03 (-1.54%)
Open$1.92
Previous Close$1.95
Day High$1.96
Day Low$1.86
52W High$3.40
52W Low$1.09
Volume—
Avg Volume1.63M
Market Cap214.94M
P/E Ratio—
EPS$-1.09
SectorBiotechnology
Analyst Ratings
Buy
14 analysts
Price Target
+1,009.4% upside
Current
$1.92
$1.92
Target
$21.30
$21.30
$14.71
$21.30 avg
$34.17
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 21.74M | 40.25M | 87.33M |
| Net Income | -147,659,235 | -246,053,159 | 8.20M |
| Profit Margin | -679.2% | -645.2% | 9.4% |
| EBITDA | -155,256,604 | -273,086,046 | 10.19M |
| Free Cash Flow | — | — | 6.96M |
| Rev Growth | -46.0% | -46.0% | +6.5% |
| Debt/Equity | 0.32 | 0.32 | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |